<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Wolinsky, Jerry S</dc:creator>
  <dc:creator>Narayana, Ponnada A</dc:creator>
  <dc:creator>Nelson, Flavia</dc:creator>
  <dc:creator>Datta, Sushmita</dc:creator>
  <dc:creator>O’Connor, Paul</dc:creator>
  <dc:creator>Confavreux, Christian</dc:creator>
  <dc:creator>Comi, Giancarlo</dc:creator>
  <dc:creator>Kappos, Ludwig</dc:creator>
  <dc:creator>Olsson, Tomas P</dc:creator>
  <dc:creator>Truffinet, Philippe</dc:creator>
  <dc:creator>Wang, Lin</dc:creator>
  <dc:creator>Miller, Aaron</dc:creator>
  <dc:creator>Freedman, Mark S</dc:creator>
  <dc:date>2013</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">&lt;jats:sec&gt;&lt;jats:title&gt;Objective:&lt;/jats:title&gt;&lt;jats:p&gt; The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Methods:&lt;/jats:title&gt;&lt;jats:p&gt; Patients ( n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Results:&lt;/jats:title&gt;&lt;jats:p&gt; After 108 weeks, increase in total lesion volume was 67.4% ( p=0.0003) and 39.4% ( p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Conclusions:&lt;/jats:title&gt;&lt;jats:p&gt; Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression. &lt;/jats:p&gt;&lt;/jats:sec&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/232094</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1177/1352458513475723</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1352-4585</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Multiple Sclerosis Journal. - SAGE Publications. - 2013, vol. 19, no. 10, p. 1310-1319</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Neurology</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Clinical Neurology</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">Magnetic resonance imaging outcomes from a phase III trial of teriflunomide</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
